May 13, 09
|
| NEW STORY |
| 08:15 ET |
Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer
|
|
Mar 09, 09
|
| 08:32 ET |
Surface Logix Raises $20 Million in Financing and Starts Phase 2b Clinical Trial of SLx-4090 in Dyslipidemia and Diabetes
|
|
Oct 14, 08
|
| 08:03 ET |
Surface Logix Appoints Keith Dionne as President and Chief Executive Officer
|
|
Sep 15, 08
|
| 08:55 ET |
Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
|
|
May 15, 08
|
| 08:17 ET |
Surface Logix Announces Executive Management Changes
|
|
Apr 15, 08
|
| 09:07 ET |
Arbios Commences Process to Seek European Marketing Approval for SEPET(TM)
|
|
Apr 10, 08
|
| 08:17 ET |
Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
|
|
Feb 05, 08
|
| 09:03 ET |
BioSeek Elects Roy Whitfield Executive Chairman of Board of Directors
|
|
Jan 29, 08
|
| 08:03 ET |
Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
|
|
Jan 24, 08
|
| 08:03 ET |
BioSeek Initiates Collaboration with Dainippon Sumitomo Pharma
|
|
Jan 08, 08
|
| 08:03 ET |
Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
|
|
Dec 05, 07
|
| 08:02 ET |
BioSeek Initiates Systems Biology Compound Evaluation Collaboration with UCB
|
|
Nov 26, 07
|
| 08:00 ET |
Surface Logix, Inc. to Present at the Piper Jaffray Health Care Conference
|
|
Nov 07, 07
|
| 08:30 ET |
BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
|
|
Nov 01, 07
|
| 09:00 ET |
Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
|
|
Oct 18, 07
|
| 08:00 ET |
Surface Logix SLx-4090 Selected Among Top 10 Most Promising Licensing Candidates In Cardiovascular Disease
|
|
Oct 05, 07
|
| 08:00 ET |
Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
|
|
Oct 03, 07
|
| 08:00 ET |
Surface Logix Inc. to Present at the 2007 Bio Investor Forum
|
|
Aug 21, 07
|
| 08:32 ET |
Surface Logix Announces the Appointment of Leland Webster as Vice President of Corporate Development
|
|
Jun 28, 07
|
| 08:17 ET |
Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease
|
|
Jun 19, 07
|
| 08:17 ET |
Surface Logix Commences Phase 2A Clinical Trial of SLx-2101 in Hypertension
|
|
Jun 06, 07
|
| 08:17 ET |
Surface Logix Starts Phase 2a Clinical Trial of SLx-4090 in Dyslipidemia
|
|
May 22, 07
|
| 08:02 ET |
BioSeek Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics With Amylin Pharmaceuticals
|
|
May 17, 07
|
| 16:02 ET |
Achillion Announces the Resignation of John C. Pottage, Jr., M.D., Senior Vice President and Chief Medical Officer
|
|
May 09, 07
|
| 07:30 ET |
Achillion Reports First Quarter 2007 Financial Results
|
|
Apr 18, 07
|
| 09:03 ET |
BioSeek Awarded ToxCast(TM) Contract by EPA to Profile Chemicals for Toxicity Using BioMAP(R) Assay Systems
|
|
Apr 16, 07
|
| 08:02 ET |
Achillion Presents Positive Data on Novel Mechanism for Treating HCV at EASL Annual Meeting
|
|
Apr 03, 07
|
| 07:30 ET |
Surface Logix Inc. Raises $20 Million in Second Tranche of Series D Financing
|
|
Mar 27, 07
|
| 16:01 ET |
Achillion Reports 2006 Fourth Quarter and Year-End Financial Results
|
|
Mar 26, 07
|
| 09:00 ET |
Surface Logix Inc. to Present at the Future Leaders in the Biotech Industry Conference
|
|
Mar 21, 07
|
| 18:30 ET |
Achillion to Host Fourth Quarter and Year End Investor Conference Call on March 27, 2007
|
|
Mar 20, 07
|
| 10:22 ET |
Achillion to Present at BioCentury and Thomson Financial's 2007 Future Leaders in the Biotech Industry Conference
|
|
Feb 26, 07
|
| 14:53 ET |
Achillion to Present at Upcoming Conferences
|
|
Feb 08, 07
|
| 16:24 ET |
Gilead and Achillion Announce Positive Antiviral Activity of NS4A Antagonist in HCV, But Discontinue GS 9132 (ACH-806) Development
|
|
| 14:42 ET |
Surface Logix Inc. to Present at BIO CEO & Investor Conference 2007
|
|
Feb 05, 07
|
| 09:00 ET |
Achillion to Participate in HIV Panel Discussion at the 2007 BIO CEO and Investor Conference
|
|
Dec 11, 06
|
| 08:45 ET |
Surface Logix Inc. to Present at the RBC Capital Markets Healthcare Conference
|
|
Nov 27, 06
|
| 08:45 ET |
Surface Logix Inc. to Present at the Piper Jaffray Health Care Conference
|
|
Nov 14, 06
|
| 08:03 ET |
Surface Logix Presents Positive Phase 1 Trial Data On SLx-4090 at American Heart Association (AHA) Annual Meeting
|
|
Nov 08, 06
|
| 16:30 ET |
Achillion Pharmaceuticals Announces Closing of Underwriters' Over-Allotment Option
|
|
Nov 02, 06
|
| 09:30 ET |
Xanthus to Present at Three Upcoming Investment Conferences
|
|
| 08:28 ET |
Surface Logix SLx-2101 Selected as One of 10 Most Promising Cardiovascular Drugs in Development
|
|
Oct 26, 06
|
| 07:30 ET |
Achillion Pharmaceuticals Announces Pricing of Its Initial Public Offering
|
|
Oct 17, 06
|
| 08:32 ET |
Surface Logix Inc. to Present at the 2006 BIO Investor Forum
|
|
Oct 03, 06
|
| 08:03 ET |
Xanthus Pharmaceuticals Expands Oncology Pipeline with Late-Stage Oral Fludarabine from Schering AG
|
|
Sep 28, 06
|
| 09:30 ET |
Xanthus' Symadex Can Reverse Disease in Preclinical Multiple Sclerosis Animal Model
|
|
Sep 14, 06
|
| 15:00 ET |
Xanthus Presents In Vitro Data Demonstrating that Symadex Is a Potent and Selective Inhibitor of FLT3
|
|
Sep 06, 06
|
| 09:06 ET |
Surface Logix Appoints W. James O'Shea to Board of Directors
|
|
| 08:30 ET |
Xanthus Pharmaceuticals Licenses Novel Cancer Targeting Agents From Schering AG, Berlin
|
|
Aug 30, 06
|
| 09:30 ET |
Xanthus Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2006
|
|
Jul 06, 06
|
| 09:01 ET |
BioSeek Initiates Compound Evaluation Collaboration with GlaxoSmithKline
|
|
Jun 28, 06
|
| 11:48 ET |
Therion Reports Results of Phase 3 PANVAC-VF Trial and Announces Plans for Company Sale
|
|
Jun 12, 06
|
| 09:58 ET |
Surface Logix Inc. to Present at the Pacific Growth Equities 2006 Life Sciences Growth Conference
|
|
Jun 05, 06
|
| 08:25 ET |
Xanthus Presents Symadex Phase 1 Results at American Society of Clinical Oncology Meeting
|
|
| 08:15 ET |
Xanthus Meets Milestone in Phase 2 Clinical Study of Xanafide for Treatment of Secondary AML
|
|
May 23, 06
|
| 09:06 ET |
Surface Logix Reports Data on SLx-2101 for Erectile Dysfunction at The American Urological Association Meeting
|
|
May 22, 06
|
| 09:23 ET |
Surface Logix Inc. Named a Red Herring 100 Winner
|
|
| 09:08 ET |
Xanthus Pharmaceuticals Appoints John Lister-James, Ph.D. as Vice President, Development
|
|
Apr 06, 06
|
| 09:58 ET |
AdipoGenix and Unigen Enter Joint Agreement to Discover and Develop Plant-Based Therapeutics That Target Fat
|
|
Apr 05, 06
|
| 09:15 ET |
Galderma to Present Corporate and Partnering Overview at the BIO 2006 Annual Meeting and Convention
|
|
Apr 03, 06
|
| 14:17 ET |
2005 Nobel Prize Winner Professor Barry Marshall to Participate in BIO 2006
|
|
| 10:35 ET |
Achillion Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
|
|
| 10:18 ET |
Xanthus Pharmaceuticals to Present at the BIO 2006 Annual International Convention
|
|
Mar 30, 06
|
| 12:21 ET |
Xanthus Pharmaceuticals to Present at the CIBC World Markets Conference
|
|
Mar 14, 06
|
| 09:12 ET |
AdipoGenix Achieves Third Milestone in Collaboration with Johnson & Johnson
|
|
| 09:04 ET |
Surface Logix Commences Phase I Trial for Novel Gastrointestinal-Specific MTP Inhibitor
|
|
Mar 01, 06
|
| 10:36 ET |
Xanthus Pharmaceuticals to Provide Update at the 26th Annual SG Cowen Health Care Conference
|
|
Feb 22, 06
|
| 09:13 ET |
Xanthus Life Sciences, Inc. Changes Name to Xanthus Pharmaceuticals, Inc.
|
|
Feb 13, 06
|
| 08:33 ET |
Xanthus' Symadex(TM) shows Remyelination in Multiple Sclerosis Animal Model
|
|
Feb 09, 06
|
| 09:49 ET |
Xanthus Life Sciences to Provide Update at the BIO CEO & Investor Conference 2006
|
|
Feb 06, 06
|
| 09:05 ET |
Dr. Derek M. Winstanly Joins Xanthus Life Sciences' Board of Directors
|
|
Jan 25, 06
|
| 08:43 ET |
Surface Logix Appoints Steven Gillis, Ph.D. to Board Of Directors
|
|
Jan 24, 06
|
| 09:34 ET |
Xanthus Strengthens Patent Estate of Xanafide(TM) for Treatment of Multiple Cancer Types
|
|
Jan 23, 06
|
| 08:10 ET |
Biovitrum and Syntonix Enter Agreement for the Joint Development and Commercialization of Recombinant Factor IX for the Treatment of Hemophilia
|
|
Jan 19, 06
|
| 08:44 ET |
Enanta Pharmaceuticals Announces Initiation of Phase 2 Studies in North America on First-in-Class Antibiotic EDP-420 for the Treatment of Community Acquired Pneumonia
|
|
Jan 17, 06
|
| 08:23 ET |
Xanthus Initiates Phase 2 Clinical Trial with Symadex in Patients with Metastatic Colorectal Cancer
|
|
Jan 03, 06
|
| 08:51 ET |
Xanthus Initiates Phase 2 Clinical Trial with Symadex in Women With Metastatic Breast Cancer
|
|
Dec 27, 05
|
| 08:10 ET |
Therion Biologics Secures $50 Million to Complete Pivotal Clinical Development Program
|
|
Dec 22, 05
|
| 13:42 ET |
Richard W. Dugan Joins Xanthus Life Sciences' Board of Directors
|
|
Dec 20, 05
|
| 10:21 ET |
Enanta Pharmaceuticals Achieves Milestone in Alliance with Shionogi & Co., Ltd.
|
|
Nov 30, 05
|
| 10:22 ET |
Surface Logix Commences Phase IIa Trial for Novel PDE5 Inhibitor SLx-2101 in Patients with Endothelial Dysfunction
|
|
Nov 22, 05
|
| 12:22 ET |
Xanthus Life Sciences to Present at the Lazard Capital Markets Life Sciences Conference
|
|
Nov 18, 05
|
| 08:37 ET |
Surface Logix Reports Data on SLx-2101 for Erectile Dysfunction and Endothelial Dysfunction at the Sexual Medicine Society of North America Meeting
|
|
Nov 15, 05
|
| 08:42 ET |
Xanthus Life Sciences Appoints J. Kris Piper as Vice President of Regulatory Affairs and Quality Assurance
|
|
Nov 04, 05
|
| 12:13 ET |
Achillion Pharmaceuticals to Present at Two Upcoming Investor Conferences
|
|
Nov 03, 05
|
| 08:05 ET |
Idera Pharmaceuticals to Present at Rodman and Renshaw Techvest 7th Annual Healthcare Conference
|
|
Nov 01, 05
|
| 08:43 ET |
Surface Logix to Present Clinical Candidate for Dyslipidemia and Obesity at the American College of Gastroenterology Scientific Meeting
|
|
Oct 31, 05
|
| 16:08 ET |
Xanthus Life Sciences to Present at Three Upcoming Investment Conferences
|
|
Oct 28, 05
|
| 08:02 ET |
Surface Logix Inc. Announces $42 Million Private Financing to Advance Multiple Clinical Programs
|
|
Oct 26, 05
|
| 08:05 ET |
Idera Pharmaceuticals Initiates Phase 1/2 Oncology Trial of HYB2055 in Combination with Chemotherapy Agents Gemcitabine and Carboplatin
|
|
Oct 21, 05
|
| 09:41 ET |
Syntonix and Boehringer Ingelheim Enter Collaboration for Up to $63 Million to Optimize Therapeutic Peptide Candidates for Inhalation
|
|
Oct 20, 05
|
| 09:04 ET |
Xanthus Initiates a Phase 2 Study Of Xanafide in Combination with ara-C for Treatment Of Secondary AML
|
|
| 08:05 ET |
Idera Pharmaceuticals Amends HYB2055 Phase 2 Renal Cell Carcinoma Protocol
|
|
Oct 18, 05
|
| 08:05 ET |
Idera Pharmaceuticals to Present at BIO InvestorForum
|
|
Oct 17, 05
|
| 12:00 ET |
Xanthus Life Sciences to Provide Update on Oncology Pipeline at the 2005 BIO InvestorForum
|
|
| 08:16 ET |
Dynogen Initiates Phase II Trial of DDP225 for Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
|
|
Oct 11, 05
|
| 08:54 ET |
Surface Logix Phase I Clinical Trial Achieves Target Profile
|
|
Sep 29, 05
|
| 09:16 ET |
Xanthus Life Sciences Awarded Grant from NCI to Develop Technology for Personalized Dosing of Anticancer Drugs
|
|
Sep 23, 05
|
| 09:33 ET |
Xanthus Life Sciences Appoints John A. McCarthy, Jr. as Senior Vice President and Chief Financial Officer
|
|
Sep 21, 05
|
| 16:08 ET |
Xanthus Life Sciences to Provide Update on Oncology Pipeline at UBS Global Life Sciences Conference
|
|
Sep 20, 05
|
| 10:12 ET |
Surface Logix Appoints Schering Executive, Marc Rubin, M.D., to Board of Directors
|
|
Sep 12, 05
|
| 08:12 ET |
Hybridon Changes Name to Idera Pharmaceuticals
|
 |
Sep 08, 05
|
| 09:33 ET |
Hybridon, Inc. to Present at ThinkEquity Growth Conference
|
|
| 08:13 ET |
Dynogen Appoints Dr. Suhail Nurbhai as Vice President, Clinical Development
|
|
Aug 04, 05
|
| 08:59 ET |
LineaGen Announces Promotion of Michael Paul, Ph.D. to President and COO
|
|
Aug 03, 05
|
| 08:47 ET |
AdipoGenix Announces the Addition of Three New Members to its Scientific Advisory Board
|
|
Jun 30, 05
|
| 08:01 ET |
Organon Launches Global Research and Biotechnology Initiative
|
|
Jun 29, 05
|
| 16:00 ET |
Organon Celebrates Opening of New Cambridge Facility -- Organon Research Center USA
|
|
Jun 21, 05
|
| 08:00 ET |
Hybridon, Inc., to Participate in Innate Immunity Panel at the BIO 2005 Annual International Convention
|
|
Jun 17, 05
|
| 09:05 ET |
Hybridon Announces the Appointment of Robert W. Karr, M.D. to its Board of Directors
|
|
| 08:52 ET |
AdipoGenix Appoints Nils Bergenhem, Ph.D. as Chief Scientific Officer
|
|
Jun 08, 05
|
| 08:33 ET |
Surface Logix Commences Phase I Trial for Novel PDE-5 Inhibitor
|
|
Jun 01, 05
|
| 01:00 ET |
Hybridon Announces Collaboration to Develop Immune Modulatory (IMO) Compounds for Asthma and Allergy
|
|
May 20, 05
|
| 13:20 ET |
Hybridon Announces $5 Million Private Financing
|
|
May 18, 05
|
| 09:05 ET |
IBM, the University of Utah and LineaGen Research Corporation Enter Broad Collaboration to Advance Clinical Genomics for Personalized Medicines and Individualized Patient Care
|
|
May 17, 05
|
| 08:14 ET |
Xanthus Presents at ASCO: Phase 1 Data Shows Significant Activity of Amonafide in Combination With ara-C for Treatment of Poor Risk AML
|
|
May 16, 05
|
| 09:07 ET |
Therion Announces Oral Presentation of Data from Phase II PROSTVAC-VF Study in Patients with Androgen-Independent Prostate Cancer at ASCO
|
|
| 08:55 ET |
Hybridon Presents Preclinical Data on Interferon-Alpha Induction by Toll-Like Receptor 9 Agonists
|
|
| 08:36 ET |
Hybridon Announces Oral Presentation of Results for Phase I Trial of IMOxine(R) at ASCO 2005
|
|
May 15, 05
|
| 08:09 ET |
Therion Announces Presentation of Follow-up Clinical Data Regarding Its Novel Targeted Cancer Therapy PANVAC-VF at ASCO
|
|
May 14, 05
|
| 11:17 ET |
Therion Announces Oral Presentation of Clinical Data on Its Targeted Cancer Therapy PROSTVAC-VF at ASCO
|
|
May 11, 05
|
| 09:05 ET |
Hybridon Publishes Data on Novel Synthetic Agonists of Toll-Like Receptor 9
|
|
May 04, 05
|
| 08:33 ET |
Xanthus Names Robert L. Capizzi, M.D., F.A.C.P. Chief Medical Officer
|
|
May 03, 05
|
| 09:06 ET |
Surface Logix Appoints Former GlaxoSmithKline Executive, William Prince, MB ChB, PhD, Senior VP of Commercial Development
|
|
| 09:05 ET |
Hybridon, Inc. to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference
|
|
Apr 27, 05
|
| 15:27 ET |
Accelerated Technologies, Inc. Announces Agreement to Sell Impella CardioSystems AG to ABIOMED, Inc.
|
|
Apr 18, 05
|
| 09:05 ET |
Hybridon Presents New Preclinical Antitumor Data at AACR Supporting its IMOxine Development Program
|
|
| 08:05 ET |
Xanthus Presents Symadex Gene Expression Study at AACR
|
|
Mar 28, 05
|
| 09:05 ET |
Hybridon Reports 2004 Financial Results
|
|